ECFS 2020 - Optimizing pharmaceutical care in cystic fibrosis

296 OPTIMIZING PHARMACEUTICAL CARE IN CYSTIC FIBROSIS INTERACTIONS IN PATIENTS ON CFTR MODULATORS CHAPTER 17 [6] Vertex Pharmaceuticals (Ireland) Limited. Symkevi 100 mg/150 mg film-coated tablets. Summary of Product Characteristics, 2018. Avail- able from: medicines/symkevi-100-mg-150-mg- film-coated-tablets-34648/smpc [7] Lexicomp Drug Interactions. 2019 Wolters Kluwer Clinical Drug Information, Inc. Available from: teractions/?source=responsive_ home#di-druglist [8] Mycology reference laboratory: service user handbook. Guidelines for antifungal drug monitoring. Public Health England Mycology Reference Laboratory. Bristol. https://www. mycology-reference-laborato- ry-mrl-service-user-handbook/mycol- ogy-reference-laboratory-service-us- er-handbook [9] Pfizer Healthcare Ireland. VFend 50mg and 200mg film-coated tablets. Summary of Product Characteristics. Available from: https://www.medi- 200mg-film-coated-tablets-34179/ smpc [10] Janssen Sciences Ireland. Sporanox 100mg Capsules. Summary of Product Characteristics. Available from: medicines/sporanox-100mg-cap- sules-33816/smpc References [1] Jordan CL, Noah TL and Henry MM. Therapeutic challenges posed by critical drug–drug interactions in cystic fibrosis. Pediatr Pulmonol. 2016; 51, S61-S70. Available from: http://dx.doi. org/10.1002/ppul.23505 . [2] Vertex Pharmaceuticals (Ireland) Limited. Kalydeco 150 mg film- coated tablets. Summary of Product Characteristics. Date of first authori- sation: 23 July 2012. Available from: kalydeco-150-mg-film-coated-tab- lets-32562/smpc [3] Vertex Pharmaceuticals (Ireland) Limited. Orkambi 200 mg/125 mg tablets and 100 mg/125 mg tablets. Summary of Product Characteristics 2015. Available from: https://www. 200-mg-125-mg-tablets-and-100mg- 125mg-tablets-33249/smpc [4] Orkambi (Lumacaftor/ Ivacaftor) Drug- Drug interactions quick reference guide. Vertex pharmaceutical incor- porated. 2018. Available from: https:// DDI_Guide.pdf [5] Symkevi (tezacaftor/ ivacaftor) + Kalydeco (ivacaftor)initiation guide. A combination regimen to treat the underlying protein defect in cystic fibrosis for multiple responsive genotypes. Vertex Pharmaceuticals Incorporated. 2018. VXR-IE-23-00005 | 11/2018.